Fuzhou

Researchers are evaluating whether adding a half-dose bolus of recombinant staphylokinase r-SAK, a clot-dissolving drug, immediately before primary percutaneous coronary intervention PCI can improve outcomes in patients with acute ST-segment elevation myocardial infarction STEMI treated within 120 minutes. This randomized, double-blind, placebo-controlled trial aims to assess the safety and efficacy of r-SAK in reducing major adverse cardiovascular events within 90 days after treatment. Participants are randomly assigned to receive either a single intravenous bolus of 5 mg r-SAK over 3 minutes or a placebo injection within 10 minutes after STEMI diagnosis. Following this, all patients undergo primary PCI within 30 to 120 minutes. The study is conducted across multiple centers and compares the effects of r-SAK versus placebo as adjunctive therapy before PCI. During the study, participants will be monitored for major adverse cardiovascular events up to 90 days, with additional assessments including cardiac and cerebrovascular events, blood biomarkers NT-proBNP, cardiac imaging by echocardiogram and cardiac magnetic resonance imaging CMR, and blood flow in coronary arteries immediately before and after PCI. Safety and efficacy will also be tracked up to one year. The total participation duration includes follow-up visits at days 7, 90, and 360 after treatment.

Researchers are evaluating HS-20093, a humanized IgG1 antibody-drug conjugate that targets B7-H3, which is commonly found on solid tumor cells. This open-label, multi-center phase 2 study focuses on Chinese adults with recurrent, locally advanced, or metastatic esophageal carcinoma and other advanced solid tumors. The study aims to assess the anti-tumor activity, safety, pharmacokinetics, and immune response of HS-20093. The study is divided into two parts phase IIa and phase IIb. In phase IIa, participants with relapsed, locally advanced, or metastatic esophageal carcinoma and other solid tumors will receive intravenous doses of HS-20093 every three weeks. Phase IIb will enroll participants specifically with relapsed, locally advanced, or metastatic esophageal squamous cell carcinoma, also receiving HS-20093 by intravenous infusion every three weeks. Treatment continues until unacceptable side effects occur or the disease progresses. Participants will undergo regular evaluations including tumor assessments according to RECIST 1.1 criteria to measure response rate, duration of response, disease control, progression-free survival, and overall survival up to 24 months. Safety is monitored through adverse event tracking up to 90 days after the last dose. Blood samples will be collected to analyze drug levels and immune reactions. The study duration includes treatment and follow-up to monitor these outcomes and overall participant health.